EANS-News: AGENNIX AG Agennix Hires Jill Porter as Senior Vice President of
Pharmaceutical Development
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Personnel
Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and Houston,
TX, June 22, 2011 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced
the appointment of Jill Porter, Ph.D. as Senior Vice President, Pharmaceutical
Development, reporting to Dr. Rajesh Malik, Chief Medical Officer. In this
position, Dr. Porter is leading all activities related to supply chain, global
production and CMC (chemistry, manufacturing and controls) for talactoferrin, an
oral immunotherapy being studied for the treatment of non-small cell lung cancer
and for severe sepsis.
Rajesh Malik, M.D., Chief Medical Officer, said, "I am very pleased to welcome
Dr. Porter to Agennix. She has extensive experience in leading production and
supply chain activities and developing strategic plans in these areas for both
development-stage and marketed biologic products. Dr. Porter is an excellent
addition to our management team in an area of critical importance, as we prepare
for a possible regulatory filing for talactoferrin and a potential commercial
launch."
Dr. Porter has nearly twenty years of biopharmaceutical industry experience. She
has held senior executive positions with responsibility for manufacturing and
process development at Taligen Therapeutics, Altus Pharmaceuticals and Alexion
Pharmaceuticals, where she worked immediately prior to joining Agennix. She
worked for many years in positions of increasing responsibility at Hoffman-La
Roche, including leading the Biopharmaceuticals department, with responsibility
for the clinical and commercial manufacturing of two biologic drugs. Dr. Porter
has experience in clinical and commercial supply chain management, as well as
with regulatory filings and product approvals. She received a Ph.D. in
agricultural engineering from Purdue University and an MBA from Columbia
University.
About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral immunotherapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in non-small
cell lung cancer, and Agennix is also continuing the development of this program
for the treatment of severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase I testing, and a topical
gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is
in Heidelberg, Germany. The Company has three sites of operation:
Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For
additional information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. There can be no
guarantee that the Company will move talactoferrin forward in development for
severe sepsis in a timely manner, if at all. Even if the results from our later
stage trials with talactoferrin, including the ongoing FORTIS-M trial in
non-small cell lung cancer, are considered positive, they may not be sufficient
to gain marketing approval in the United States or any other country, and the
regulatory authorities may require additional information, data and/or further
pre-clinical or clinical studies to support approval. In such event, there can
be no guarantee that the Company will have or be able to obtain the financial
resources to conduct any such additional studies or that such studies will yield
results sufficient for approval. Forward-looking statements speak only as of
the date on which they are made and Agennix undertakes no obligation to update
these forward-looking statements, even if new information becomes available in
the future.
Agennix(TM) is a trademark of the Agennix group.
Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English